This document provides a summary of references and documents related to mRNA vaccines. It aims to report interesting references that can help better understand what independent researchers have found, mainly focused on the public debate around the presence or absence of graphene derivatives in some COVID-19 vaccine vials. Relevant classic articles, white papers, and other documents are useful for clarifying crucial aspects of the infectious disease, its epidemiology, and the efficacy of preventive, therapeutic, or vaccine measures. While some of the referenced studies and documents have limitations, reviewing them can generate hypotheses or open public discussion on important topics, given mRNA vaccines were introduced via emergency authorization with reduced testing time and lack of official quality information on raw materials.

1. Jfp +32(800) 709-48 manuscripts@iomcworld.com
Journal of ForensicPathology
ISSN - 2684-1312
AuthorGuidelines
Articlesinprocess
Abstract
Relevant article , White Papers and other documents concerning
The m RNA VACCINE: An interesting collection useful to better
understand some phenomena and to generate hypotesys
Luisetto m, NaseerAlmukthar, EdbeyK, Tarro G, Nili B. Ahmadabadi
Aimof thiswork isto reportsome ineterstingreferenceanddocumentrelatedmRNA vaccine . Everycited
reference canact as an instrumenttobetter understandwhatsome independentresearcherfinded: this
workis mainlyfocusedontthe publicdebate related presence /absence of graphene derivatesinsome
vaccine vialsforcovid-19.Relevantclassicarticle orWhite paperorotherkindof documentare useful
instrumenttobetterclarify Some crucial aspectsof thisinfectiousdisease ,itsepidemiologyandefficacy
of the measure adopted( preventive,therapeuticorvaccine).If the reviewedarticle show anintrinsic
recognizedinternational valueotherkindof source like White Paperorotherdocumentcan be of interest
to generate hypotesysortoopenpublicdiscussiononcrucial topics.For thisreason itis useful touse this
methodalsointhe discussionrelated of impurity profile innew innovative bio-pharmaceuticalslike the m
RNA vaccine. The factthat thisproducts wasintroducedwithanemergencyauthorization,whitreduced
time of sperimentationanddue bylackof official quality informationsrelatedsome raw materialsused
authorize usto use alsothismethod.Evenif the internationalofficial regulatoryagency notfindedthis
substantie inthe control forrelease the lotsitisinterestingtomore deeplyinvestigateonwhatfinde dby
independentresearcherinsome vialsof vaccine orinsample patientsbloodaftervaccination.This
reference evenif notare a smokinggunthe same can stimulate the reasoningaboutthe general concept
involved.Itisneeded,readingthiswork,toconsiderthe intrinsic limitationof some of the studyresearch
reported ( white paper) or the otherdocuments.
09/08/2022